CDEK
← All drugs Report issue

Mezigdomide

Small moleculeexperimental

Clinical trial activity

23 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
19
Phase 2
9
Phase 3
2
Phase 4
0

Earliest trial started Feb 6, 2018 (NCT03374085)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N#Cc1ccc(N2CCN(Cc3ccc(COc4cccc5c4CN([C@H]4CCC(=O)NC4=O)C5=O)cc3)CC2)c(F)c1
Mol. weight
567.62 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07032714Phase 1Dec 16, 2025Celgene, Harvard University, Johnson and Johnson
NCT06988488Phase 1/Phase 2 (Phase 2)Oct 7, 2025Bristol-Myers Squibb, Celgene
NCT07105059Phase 1Aug 8, 2025Bristol-Myers Squibb, Johnson and Johnson, Memorial Sloan-Kettering Cancer Center
NCT06627751Phase 2Nov 1, 2024State University of New York, Buffalo
NCT06645678Phase 1/Phase 2 (Phase 2)Oct 24, 2024Seoul National University
NCT06318676Phase 1Mar 21, 2024Bristol-Myers Squibb, Celgene
NCT06163898Phase 1/Phase 2 (Phase 2)Jan 15, 2024Bristol-Myers Squibb, Celgene
NCT05981209Phase 1Dec 31, 2023Ohio State University
NCT06121843Phase 1Dec 31, 2023Bristol-Myers Squibb
NCT06048250Phase 1Dec 28, 2023City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06050512Phase 1/Phase 2 (Phase 2)Oct 2, 2023Bristol-Myers Squibb, University of Pittsburgh
NCT05707390Phase 1Feb 20, 2023Bristol-Myers Squibb
NCT05552976Phase 3Dec 15, 2022Bristol-Myers Squibb
NCT05372354Phase 1/Phase 2 (Phase 2)Oct 31, 2022Bristol-Myers Squibb
NCT05519085Phase 3Sep 20, 2022Bristol-Myers Squibb, Celgene
NCT05389722Phase 1Jun 9, 2022Bristol-Myers Squibb
NCT04839809Phase 1Jan 19, 2021Celgene
NCT04560738Phase 1Oct 8, 2020Bristol-Myers Squibb, Celgene
NCT04211545Phase 1Oct 21, 2019Celgene
NCT03989414Phase 1/Phase 2 (Phase 2)Aug 1, 2019Celgene
Showing 20 of 23 trials
Page 1 / 2

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit13642020
CelgeneFor profit111032018
Johnson and JohnsonFor profit2012025
City of Hope National Medical CenterAcademic/Hospital1112023
Harvard UniversityAcademic/Hospital1112025
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1112025
National Cancer Institute (NCI)Government1012023
Ohio State UniversityAcademic/Hospital1112023
Seoul National UniversityAcademic/Hospital1112024
State University of New York, BuffaloAcademic/Hospital1112024
University of PittsburghAcademic/Hospital1112023
11 organizations
Page 1 / 1